Submitted:
23 March 2020
Posted:
24 March 2020
Read the latest preprint version here
Preprints on COVID-19 and SARS-CoV-2
Abstract
The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2. Making use of a large quantity of published reports in which human/rodent ACE2 pathway inhibitors were administered in vivo, I have hypothesized a possible therapeutic pharmacological intervention through an inhibition strategy of ACE2 pathway for SARS-CoV-2 patients who are suffering from critical, advanced and untreatable stages of the disease.
Keywords:
Severe Acute Respiratory Syndrome Coronavirus-2
; (soluble) ACE2
; eosinophil
; asthma
; IL-10
; IL-6
; Lung fibrosis
; Angiotensin
; hypoxia
; infarction
; hypertension
; hypercapnic acidosis
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
